...BRCA1 mutation status, and follow-up data to compare the clinicopathologic and immunohistochemical features of TN tumors...
...BRCA1/2 mutations who benefited from bilateral mastectomy. Local failure risk prediction is currently unfeasible among f...
Although the increase in risk of developing breast, ovarian, and prostate cancer in BRCA1 and BRCA2 mutation carriers ha...
...BRCA1 of 2 testing before July 2005 were sent a follow-up patient survey. The authors compared responses of women who te...
...BRCA1*185delAG, BRCA1*5382insC, and BRCA2*6174delT) account for 95% of the detectable BRCA mutations in breast and ovari...
...BRCA1-associated tumors. These studies thus reveal a key role for polarity signaling and the control of morphologic tran...
...BRCA1 in the 1990s, much work has been carried out to identify further breast cancer susceptibility genes. This has led ...
...BRCA1 or BRCA2. Functionally, CIP2A depletion was shown to inhibit the expression of its target protein c-Myc. Loss of C...
...BRCA1), and genes of the Fanconi anemia pathway. Most interestingly, some of these alterations become the Achilles heel ...
...BRCA1 inactivation, and many chromosomal alterations. New target molecules for the treatment of TNBCs are under extensiv...
Contact
No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong
Qilu Normal University · Genelibs Bioinformatics Lab
750 Shunhua Rd, Jinan
2F, Bldg F, University Science Park
Tel: 0531-88819269
WeChat Official Account
Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.
Business Email
E-mail: product@genelibs.com
Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2
